


PRODUCT INFORMATION



Guanfacine-¹³C,¹⁵N₃

Item No. 30143

CAS Registry No.: 1189924-28-4
Formal Name: N-(amino-¹⁵N-imino-¹⁵N-methyl-¹³C)-2,6-dichloro-benzeneacetamide-¹⁵N
MF: C₈[¹³C]H₉Cl₂[¹⁵N]₃O
FW: 250.1
Purity: ≥95%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Guanfacine-¹³C,¹⁵N₃ is supplied as a solid. A stock solution may be made by dissolving the guanfacine-¹³C,¹⁵N₃ in the solvent of choice, which should be purged with an inert gas. Guanfacine-¹³C,¹⁵N₃ is slightly soluble in methanol (when sonicated).

Description

Guanfacine-¹³C,¹⁵N₃ is intended for use as an internal standard for the quantification of guanfacine (Item No. 22907) by GC- or LC-MS. Guanfacine is an α_2 -adrenergic receptor (α_2 -AR) agonist with K_i values of 93, 1,380, and 3,890 nM for α_{2A} -, α_{2B} -, and α_{2C} -ARs, respectively, in a radioligand binding assay.¹ It has EC_{50} values of 52, 288, and 602 nM for α_{2A} -, α_{2B} -, and α_{2C} -ARs, respectively, for stimulated [³⁵S]GTP γ S binding. It also binds to imidazoline receptor 1 (K_i = 19 nM in a radioligand binding assay).² Guanfacine (0.3-5 mg/kg) binds to adrenergic receptors in the central nervous system and lowers blood pressure in hypertensive rats in a dose-dependent manner.³ It also improves spatial working memory deficits induced by hypobaric hypoxia in rats.⁴ Formulations containing guanfacine are used in the treatment of high blood pressure and attention deficit hyperactivity disorder (ADHD).

References

1. Jasper, J.R., Lesnick, J.D., Chang, L.K., *et al.* Ligand efficacy and potency at recombinant α_2 adrenergic receptors: Agonist-mediated [³⁵S]GTP γ S binding. *Biochem. Pharmacol.* **55(7)**, 1035-1043 (1998).
2. Nikolic, K., Filipic, S., and Agbaba, D. QSAR study of imidazoline antihypertensive drugs. *Bioorg. Med. Chem.* **16(15)**, 7134-7140 (2008).
3. Scholtysik, G. Pharmacology of guanfacine. *Br. J. Clin. Pharmacol.* **10(Suppl 1)**, 21S-24S (1980).
4. Kausar, H., Sahu, S., Kumar, S., *et al.* Guanfacine is an effective countermeasure for hypobaric hypoxia-induced cognitive decline. *Neuroscience* **254**, 110-119 (2013).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/07/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM